曲妥珠单抗联合TAC化疗方案治疗Her-2阳性乳腺癌患者的效果分析

Efficacy of trastuzumab combined with TAC chemotherapy in patients with HER-2 positive breast cancer

目的:探究曲妥珠单抗联合TAC化疗方案治疗人表皮生长因子2(Her-2)阳性乳腺癌(BC)患者的效果及对血清肿瘤标志物水平的影响。方法:选取94例Her-2阳性BC患者,根据治疗方案不同分为两组,每组各47例。常规组采用TAC化疗方案治疗,联合组于常规组基础上加用曲妥珠单抗治疗。对比两组疗效及治疗前后免疫功能、血清肿瘤标志物[多肽特异性抗原(TPS)、癌胚抗原(CEA)、糖蛋白153(CAl53)]水平、孕激素受体(PR)、雌激素受体(ER)、细胞核相关抗原(Ki67)表达。结果:联合组疾病控制率高于常规组(P<0.05);治疗后,联合组血清CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于常规组(P<0.05);治疗后,联合组血清TPS、CEA、CAl53水平低于常规组(P<0.05);治疗后,联合组PR、ER表达高于常规组,Ki67表达低于常规组(P<0.05)。结论:Her-2阳性BC患者采用曲妥珠单抗联合TAC化疗方案治疗,可改善免疫功能,调节PR、ER、Ki67表达,降低血清肿瘤标志物水平。

Objective: To investigate the efficacy of trastuzumab combined with TAC chemotherapy in the treatment of patients with human epidermal growth factor 2(HER-2)positive breast cancer(BC)and its influence on the serum tumor marker levels. Methods: 94 BC patients with positive HER-2 were divided into 2 groups according to different treatment regimens, each with 47 cases. The conventional group were treated with TAC chemotherapy regimen, while the combination group were additionally treated with trastuzumab on the basis of the conventional group. The efficacy and immune function, serum tumor markers [tissue polypeptide specific antigen(TPS), carcino-embryonic antigen(CEA)and Cal53] levels, progesterone receptor(PR), estrogen receptor(ER), and nuclear associated antigen(Ki67)expressions were compared between the two groups before and after treatment. Results: The disease control rate of combination group was higher than that of routine group(P<0.05);after treatment, the serum levels of CD3^(+), CD4^(+) and CD4^(+)/CD8^(+) in combination group were higher than those in conventional group(P<0.05);the serum levels of TPS, CEA and CA153 in combination group were lower than those in conventional group(P<0.05);the expressions of PR and ER in combination group were higher than those in conventional group, but the expression of Ki67 was lower than that in conventional group(P<0.05). Conclusion: Trastuzumab combined with TAC chemotherapy can improve the immune function, regulate the expressions of PR, ER and Ki67, and reduce the level of serum tumor markers in patients.